Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II Study of AZD4877 (a Novel Anti-Mitotic Agent) in Advanced Bladder Cancer
This study is ongoing, but not recruiting participants.
Study NCT00661609   Information provided by AstraZeneca
First Received: April 16, 2008   Last Updated: April 30, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bladder Cancer
Transitional Cell Bladder Cancer
Urethra Cancer
Ureter Cancer
Renal Pelvis Cancer
Additional conditions recognized in this trial
Pelvic Neoplasms
Ureteral Neoplasms
Urethral Neoplasms
Urinary Bladder Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Site
Ureteral Diseases
Urethral Diseases
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
AZD4877
Additional drug interventions recognized in this trial
Antimitotic Agents
More general drug interventions related to this trial
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services